1115 related articles for article (PubMed ID: 26546453)
1. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
Reardon DA; Gokhale PC; Klein SR; Ligon KL; Rodig SJ; Ramkissoon SH; Jones KL; Conway AS; Liao X; Zhou J; Wen PY; Van Den Abbeele AD; Hodi FS; Qin L; Kohl NE; Sharpe AH; Dranoff G; Freeman GJ
Cancer Immunol Res; 2016 Feb; 4(2):124-35. PubMed ID: 26546453
[TBL] [Abstract][Full Text] [Related]
2. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
3. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model.
Mathios D; Park CK; Marcus WD; Alter S; Rhode PR; Jeng EK; Wong HC; Pardoll DM; Lim M
Int J Cancer; 2016 Jan; 138(1):187-94. PubMed ID: 26174883
[TBL] [Abstract][Full Text] [Related]
5. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
[TBL] [Abstract][Full Text] [Related]
6. Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8
Hutmacher C; Gonzalo Núñez N; Liuzzi AR; Becher B; Neri D
Cancer Immunol Res; 2019 Apr; 7(4):572-583. PubMed ID: 30782667
[TBL] [Abstract][Full Text] [Related]
7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
8. Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.
Kroon P; Gadiot J; Peeters M; Gasparini A; Deken MA; Yagita H; Verheij M; Borst J; Blank CU; Verbrugge I
Cancer Immunol Immunother; 2016 Jun; 65(6):753-63. PubMed ID: 27160390
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
[TBL] [Abstract][Full Text] [Related]
11. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
Olivo Pimentel V; Marcus D; van der Wiel AM; Lieuwes NG; Biemans R; Lieverse RI; Neri D; Theys J; Yaromina A; Dubois LJ; Lambin P
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688020
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.
Das R; Verma R; Sznol M; Boddupalli CS; Gettinger SN; Kluger H; Callahan M; Wolchok JD; Halaban R; Dhodapkar MV; Dhodapkar KM
J Immunol; 2015 Feb; 194(3):950-9. PubMed ID: 25539810
[TBL] [Abstract][Full Text] [Related]
14. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM
J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Blockade in Cancer Therapy.
Postow MA; Callahan MK; Wolchok JD
J Clin Oncol; 2015 Jun; 33(17):1974-82. PubMed ID: 25605845
[TBL] [Abstract][Full Text] [Related]
16. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies.
Evans EE; Jonason AS; Bussler H; Torno S; Veeraraghavan J; Reilly C; Doherty MA; Seils J; Winter LA; Mallow C; Kirk R; Howell A; Giralico S; Scrivens M; Klimatcheva K; Fisher TL; Bowers WJ; Paris M; Smith ES; Zauderer M
Cancer Immunol Res; 2015 Jun; 3(6):689-701. PubMed ID: 25614511
[TBL] [Abstract][Full Text] [Related]
17. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
20. Enhanced antitumor efficacy through microwave ablation in combination with immune checkpoints blockade in breast cancer: A pre-clinical study in a murine model.
Zhu J; Yu M; Chen L; Kong P; Li L; Ma G; Ge H; Cui Y; Li Z; Pan H; Xie H; Zhou W; Wang S
Diagn Interv Imaging; 2018 Mar; 99(3):135-142. PubMed ID: 29398572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
